GenScript

GenScript

GenScript is a Piscataway, New Jersey-based company.

GenScript is a genetics and biotechnology company that was founded by Fangliang Zhang in 2002. It is a contract research organization (CRO) that specializes in biological research and drug discovery/development. The company also offers drug discovery and antibody services.

Timeline

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
GenScript ProBio
February 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Le 21 février 2021, GenScript ProBio et SunRock Biopharma, une société spécialisée dans le développement d'anticorps thérapeutiques ciblant le...
GenScript ProBio
February 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- El 21 de febrero de 2021, GenScript ProBio y SunRock Biopharma, una compañía centrada en el desarrollo de terapéuticos de anticuerpos dirigidos...
Kyle Blankenship
December 3, 2020
FierceBiotech
Arena Pharma R&D chief Cabell leaves company after six months on the job; Zai Lab appoints Roche vet Sandler to research post; 4D hires executive trio.
Conor Hale
December 4, 2020
FierceBiotech
Everlywell's sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year--and investors have taken notice. The company's second venture capital round this year has raised $175 million to help accelerate its efforts and expand further into retail stores nationwide.
Nick Paul
December 4, 2020
FierceBiotech
Antibody levels stayed elevated in the 90 days after people received the second dose of Moderna's COVID-19 vaccine, raising hopes that the prophylactic can provide protection for one year.
Conor Hale
December 3, 2020
FierceBiotech
The Tel Aviv-based venture capital firm focused on digital health has closed a new fund totaling $170 million, and plans to invest in startups across the globe with a new focus on the Asia Pacific region.
Conor Hale
December 3, 2020
FierceBiotech
After restructuring its heart valve operations and culling one of its programs last year, LivaNova has decided to sell off the flagging business to the Swiss firm Gyrus Capital, for a base purchase price of €60 million, or $73 million U.S.
Amirah Al Idrus
December 3, 2020
FierceBiotech
4D Molecular Therapeutics raised $75 million in June to get several gene therapy programs into and through the clinic. Now, it's adding a trio of executives to spearhead its work in heart, eye and lung diseases as it looks to shepherd treatments in those focus areas forward.
Ben Adams
December 3, 2020
FierceBiotech
Germany's Merck is signing up to a small upfront but potentially huge biobucks pact with U.K.-U.S. biotech Artios.
Ben Adams
December 3, 2020
FierceBiotech
London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers on both sides of the pond participate in more clinical studies.
Ben Adams
December 2, 2020
FierceBiotech
Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.
Conor Hale
December 1, 2020
FierceBiotech
After a brief stint in the antidote business, Boston Scientific has moved to hive off the specialty pharmaceuticals division it picked up through last year's $4.2 billion acquisition of the British oncology devicemaker BTG. A new, $800 million cash deal will transfer the entire operation to the European pharma group Serb.
Arlene Weintraub
November 30, 2020
FierceBiotech
Researchers at the Centre for Genomic Regulation in Barcelona are developing a stem cell treatment for retinal degeneration that focuses on two chemokine receptors that play an important role in cell signaling. The altered cells migrated in high numbers to degenerating retinal tissue and preserved its function, they reported.
Ben Adams
December 1, 2020
FierceBiotech
A host of top-suite venture capitalist firms have helped put together a meaty series A for an immuno-oncology biotech 2.0.
Ben Adams
November 30, 2020
FierceBiotech
As Moderna continues to drip-feed the latest data from its late-stage COVID-19 vaccine effort, it has updated the shot's efficacy figure.
Conor Hale
November 29, 2020
FierceBiotech
The U.K. National Health Service is looking to get an early start on the international rollout of Grail's multi-cancer blood test with a pilot program spanning 165,000 people.
Conor Hale
November 29, 2020
FierceBiotech
Nominations are open for private startups and companies from across the globe, whether they're currently working in COVID-19 or not.
Angus Liu
November 30, 2020
FierceBiotech
Two research teams have discovered drug combinations that may make it possible to translate CAR-T cell therapies to solid tumors. Both approaches are designed to overcome challenges in the tumor microenvironment that impede the ability of T cells to penetrate cancer cells and kill them.
Conor Hale
November 29, 2020
FierceBiotech
Shortly after raising $65 million to grow its remote monitoring platforms, AliveCor has secured FDA clearance for its new generation of ECG-reading algorithms that spot a wider range of arrhythmias and potential heart conditions.
Conor Hale
November 30, 2020
FierceBiotech
A deep learning computer model developed by researchers at Massachusetts General Hospital was able to identify subtle information in breast cancer images that could help better predict a woman's chances of developing the disease.
SHOW MORE
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.